EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Interconnected Pathways and Emerging Therapies in Chronic Kidney Disease and Heart Failure: A Comprehensive Review

Johann Bauersachs iD, Eri Toda Kato, Janani Rangaswami

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15345 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Johann Bauersachs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Heart Failure, Renal Insufficiency, Chronic, Disease Management. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) and chronic heart failure (HF) frequently coexist and, when comorbid, are associated with poorer outcomes. These two diseases have common risk factors, such as diabetes, obesity and hypertension, and common pathophysiological connected mechanisms, including inflammation, endothelial dysfunction, neurohormonal activation and fibrosis. Early diagnosis and intervention are important to slow CKD progression and reduce HF events. Shared therapeutic targets for CKD and HF include the renin–angiotensin system (RAS), sodium-glucose cotransporter 2 (SGLT2), mineralocorticoid receptor (MR) and glucagon-like peptide-1 (GLP-1) receptor. For the management of CKD, current treatment guidelines recommend the use of RAS inhibitors, SGLT2 inhibitors, the nonsteroidal MR antagonist finerenone and GLP-1 receptor agonists. Challenges in the management of patients with CKD and HF include the presence of other comorbidities, leading to polypharmacy. This review highlights gaps and opportunities for improving the management of patients with CKD and chronic HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureRenal Insufficiency, ChronicDisease ManagementHumansRenin-Angiotensin SystemSodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor AntagonistsGlobal Health

Stichwörter der Autor:innen

Chronic heart failureChronic kidney diseaseGlucagon‐like peptide‐1 receptor agonistMineralocorticoid receptor antagonistPathogenesisSodium‐glucose cotransporter 2 inhibitor

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
  • Department of Cardiovascular Medicine and Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
  • George Washington University, Washington, DC, USA.

ORCID-Profile: Johann Bauersachs

Zitieren

APA

Bauersachs, J., Kato, E. T., & Rangaswami, J. (2025). Interconnected Pathways and Emerging Therapies in Chronic Kidney Disease and Heart Failure: A Comprehensive Review. ESC Heart Failure. https://doi.org/10.1002/ehf2.15345

Vancouver

Bauersachs J, Kato ET, Rangaswami J. Interconnected Pathways and Emerging Therapies in Chronic Kidney Disease and Heart Failure: A Comprehensive Review. ESC Heart Failure. 2025. doi:10.1002/ehf2.15345

BibTeX
@article{Bauersachs2025,
  author = {Bauersachs, Johann and Kato, Eri Toda and Rangaswami, Janani},
  title = {Interconnected Pathways and Emerging Therapies in Chronic Kidney Disease and Heart Failure: A Comprehensive Review},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15345}
}
Kostenlos starten →